Import Your Data

FAQ

More QuickView FAQs

QuickView

0
Meta-
Analysis

Bookmark Forward

QuickView for Valrubicin (compound)

Summary
General Info

PubChem

PubChem Compound 3794430

PubChem Compound 3794430

Name:	valrubicin
PubChem Compound ID:	3794430
Molecular formula:	C₃₄H₃₆F₃NO₁₃
Molecular weight:	723.644 g/mol

DrugBank

Identification

Name:	valrubicin
Name (isomeric):	DB00385
Drug Type:	small molecule
Synonyms:	Antibiotic Ad 32
Brand:	Valstar Preservative Free, Valstar
Category:	Antineoplastic Agents
CAS number:	56124-62-0

Pharmacology

Indication:	For the treatment of cancer of the bladder.
Pharmacology:	Valrubicin is a semisynthetic analog of the anthracycline doxorubicin, and is administered by infusion directly into the bladder.
Mechanism of Action:	Valrubicin is an anthracycline that affects a variety of inter-related biological functions, most of which involve nucleic acid metabolism. It readily penetrates into cells, where after DNA intercalation, it inhibits the incorporation of nucleosides into nucleic acids, causes extensive chromosomal damage, and arrests cell cycle in G2. Although valr... show more » Valrubicin is an anthracycline that affects a variety of inter-related biological functions, most of which involve nucleic acid metabolism. It readily penetrates into cells, where after DNA intercalation, it inhibits the incorporation of nucleosides into nucleic acids, causes extensive chromosomal damage, and arrests cell cycle in G2. Although valrubicin does not bind strongly to DNA, a principal mechanism of its action, mediated by valrubicin metabolites, is interference with the normal DNA breaking-resealing action of DNA topoisomerase II. show less «
Protein binding:	>99%
Biotransformation:	Valrubicin is metabolized to two primary metabolites: N-trifluoroacetyladriamycin and N-trifluoroacetyladriamycinol.
Toxicity:	The primary anticipated complications of overdosage associated with intravesical administration would be consistent with irritable bladder symptoms. Myelosuppression is possible if valrubicin is inadvertently administered systemically or if significant systemic exposure occurs following intravesical administration (e.g., in patients with bladder/rupture perforation). The maximum tolerated dose in humans by either intraperitoneal or intravenous administration is 600 mg/m².
Affected organisms:	Humans and other mammals

Interactions

Drug interaction:

Natalizumab	Valrubicin may increase Natalizumab toxicity. Concurrent therapy should be avoided.
Docetaxel	The taxane derivative, Docetaxel, may increase Valrubicin toxicity. Consider alternate therapy or monitor for toxic effects.
Paclitaxel	The taxane derivative, Paclitaxel, may increase Valrubicin toxicity. Consider alternate therapy or monitor for toxic effects.
Trastuzumab	Trastuzumab may increase the cardiotoxicity of Valrubicin. Signs and symptoms of cardiac dysfunction should be monitored for frequently. Increased risk of heart failure. Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.

Targets

DNA topoisomerase 2-alpha